Anatomical Therapeutic Chemical • J05AE05 • amprenavir

J Antiinfectives for systemic use

J01 Antibacterials for systemic use

J02 Antimycotics for systemic use

J04 Antimycobacterials

J05 Antivirals for systemic use

J05A Direct acting antivirals

J05AA Thiosemicarbazones

J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors

J05AC Cyclic amines

J05AD Phosphonic acid derivatives

J05AE Protease inhibitors

J05AE01 saquinavir Indicated for: HIV-1 infection

J05AE02 indinavir Indicated for: HIV-1 infection

J05AE03 ritonavir Indicated for: HIV-1 infection

J05AE04 nelfinavir Indicated for: HIV-1 infection

J05AE05 amprenavir Indicated for: HIV-1 infection

J05AE06 lopinavir + ritonavir Indicated for: HIV-1 infection

J05AE07 fosamprenavir Indicated for: HIV-1 infection

J05AE08 atazanavir Indicated for: HIV-1 infection

J05AE09 tipranavir Indicated for: HIV-1 infection

J05AE10 darunavir Indicated for: HIV-1 infection

J05AE11 telaprevir Indicated for: chronic hepatitis C

J05AE12 boceprevir Indicated for: chronic hepatitis C

J05AE14 simeprevir Indicated for: chronic hepatitis C

J05AE30 nirmatrelvir + ritonavir Indicated for: COVID-19

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors

J05AG Non-nucleoside reverse transcriptase inhibitors

J05AH Neuraminidase inhibitors

J05AJ Integrase inhibitors

J05AP Antivirals for treatment of HIV infections

J05AR Antivirals for treatment of HIV infections, combinations

J05AX Other antivirals

J06 Immune sera and immunoglobulins

J07 Vaccines